Clinical trials located in

Northampton

Northampton city is located in United Kingdom. Currently, 8 clinical trials are being conducted in this city.

Northampton, a historic city in the heart of England, boasts a rich tapestry of heritage and culture. Known for its medieval architecture, the city’s market square is one of the oldest and largest in the country. Northampton has a significant place in England’s history, notably during the English Civil War. The city was also a major center for shoemaking and leather industries, a legacy that lives on through high-quality footwear production. The University of Northampton adds a vibrant, academic atmosphere, while the Northampton Museum and Art Gallery showcases the city’s artistic and historical treasures.

  • CT-EU-00116351

    Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    • Interferon-Alpha
    • Hydroxycarbamide
    • Ruxolitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Breast cancer treatment study: Dato-DXd and durvalumab

    This clinical trial is a comprehensive study aimed at evaluating the effectiveness and safety of advanced treatments for breast cancer, specifically targeting triple-negative and hormone receptor-low/HER2-negative types. The study involves two groups of participants. One group will receive a combination of Dato-DXd and durvalumab as a neoadjuvant (pre-surgery) treatment, followed by durvalumab as an adjuvant (post-surgery) therapy, with or without additional chemotherapy. The other group will be treated with pembrolizumab plus chemotherapy as both neoadjuvant and adjuvant therapies. The goal is to see which method is better at treating the cancer. Additional objectives include evaluating overall survival, distant disease-free survival, and participant-reported outcomes related to symptoms, physical function, fatigue, and quality of life.

    • Epirubicin
    • Doxorubicin
    • Dato-DXd
    • Carboplatin
    • Pembrolizumab
    • olaparib
    • Capecitabine
    • Durvalumab
    • Cyclophosphamide
    • Paclitaxel
  • Comparing camizestrant with standard therapy in early breast cancer treatment

    This study, known as CAMBRIA-2, aims to test a medication called Camizestrant for treating early-stage breast cancer that is ER+ and HER2-. It will compare Camizestrant with the standard treatments currently used, which are either Aromatase Inhibitor or Tamoxifen. The study is specifically focused on patients with ER+/HER2- breast cancer who are at high or medium-high risk of their cancer returning. Before they can participate, these patients must have finished all planned cancer treatments, such as surgery or chemotherapy, and currently show no signs of the disease. The main goal of the study is to see whether Camizestrant helps to prevent breast cancer from coming back. This would be measured by looking at the time from when patients join the study to when they first see their breast cancer return, or unfortunately, pass away. The study also aims to see whether Camizestrant improves other measures, such as overall survival and quality of life.

    • camizestrant
    • Abemaciclib
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Dato-DXd versus Standard Chemotherapy in Advanced Triple-negative Breast Cancer Study

    This clinical trial investigates a new treatment, Dato-DXd, compared to standard chemotherapy for patients with triple-negative breast cancer that is locally recurrent, inoperable, or metastatic and not suitable for PD-1/PD-L1 inhibitor therapy. The study, open to adults, aims to assess the treatment’s effectiveness and safety through random assignment to either Dato-DXd or investigator-chosen chemotherapy. The trial seeks 600 participants and involves regular monitoring of health and progression of the disease. It emphasizes patient eligibility based on specific health criteria and the nature of their breast cancer.

    • Eribulin mesylate
    • Dato-DXd
    • Carboplatin
    • nab-Paclitaxel
    • Capecitabine
    • Paclitaxel
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.